DexCom, Inc., a medical device company, engages in the design, development, and commercialization of continuous glucose monitoring systems for people with diabetes in the United States. The company offers FDA approved SEVEN, which includes a disposable sensor that can be inserted by a patient and used continuously for up to seven days; a transmitter; and a small handheld receiver. Its SEVEN system also received CE Mark approval for commercialization in the European Union and the countries in Asia and Latin America that recognize the CE Mark. DexCom has a collaboration agreement with Edwards Lifesciences LLC to develop products for continuously monitoring blood glucose levels in patients hospitalized for various conditions. The company was founded in 1999 and is headquartered in San Diego, California.